Form 4: Inhibrx Biosciences CFO Kelly Deck Granted Stock Options Following Sanofi Merger
SEC Form 4 Filing
Following the merger of Inhibrx, Inc. with a Sanofi subsidiary, CFO Kelly Deck received stock options for 175,000 shares.
Summary
- Kelly Deck, the Chief Financial Officer of Inhibrx Biosciences, Inc., was granted stock options on May 30, 2024.
- The stock option allows Deck to purchase 175,000 shares of Inhibrx Biosciences common stock at an exercise price of $15.86 per share.
- The options vest over a four-year period, with 25% becoming exercisable on May 30, 2025, and the remainder vesting monthly over the subsequent 36 months.
- The stock option expires on May 30, 2034.
- This grant follows the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance following the merger.
Positives
- The granting of stock options to the CFO aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives, especially following significant corporate events like mergers.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives.
- The vesting schedule of 25% after one year followed by monthly vesting is a typical arrangement.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's success.
- Employees may see this as a sign of stability and future growth following the merger.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of the stock option grant and the merger consummation. |
| 05/30/2025 | Date when 25% of the stock options become exercisable. |
| 05/30/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.